Beverly Hills Private Wealth LLC Has $3 Million Position in Novo Nordisk A/S (NYSE:NVO)

Beverly Hills Private Wealth LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 19.5% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,203 shares of the company's stock after acquiring an additional 7,048 shares during the period. Beverly Hills Private Wealth LLC's holdings in Novo Nordisk A/S were worth $3,000,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Strategic Investment Solutions Inc. IL increased its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $27,000. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $29,000. Finally, Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $33,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 1.1%

NVO stock opened at $69.05 on Monday. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $143.69. The business's 50 day moving average price is $69.96 and its two-hundred day moving average price is $75.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The company has a market capitalization of $308.31 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion during the quarter. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on NVO. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.